Specific sequence changes in codons 70 and 91 of the hepatitis C virus genotype 1b (HCV GT1b) core gene have been associated with increased risk of hepatocellular carcinoma (HCC). Essentially all previous studies were conducted in Asian populations with a wide range of liver disease, and none were conducted specifically in GT1a-infected individuals. We conducted a pilot study in a multiethnic population in the USA with HCV-related cirrhosis to determine if this association extended to GT1a-infected individuals and to determine if other sequence changes in the HCV core gene were associated with HCC risk. HCV core gene sequences from sera of 90 GT1 HCV carriers with cirrhosis (42 with HCC) were analysed using standard RT-PCRbased procedures. Nucleotide sequence data were compared with reference sequences available from GenBank. The frequency of sequence changes in codon 91 was not statistically different between HCC (7/19) and non-HCC (11/22) GT1b carriers. In GT1a carriers, sequence changes in codon 91 were observed less often than in GT1b carriers but were not observed in non-HCC subjects (4/23 vs 0/26, P50.03, Fisher's exact test). Sequence changes in codon 70 were not distributed differently between HCC and non-HCC GT1a and 1b carriers. Most importantly, for GT1a carriers, a panel of specific nucleotide changes in other codons was collectively present in all subjects with HCC, but not in any of the non-HCC patients. The utility of this test panel for early detection of HCC in GT1a-infected individuals needs to be assessed in larger populations, including longitudinal studies.
INTRODUCTION
Hepatocellular carcinoma (HCC), the most common type of primary liver tumour, arises directly from hepatocytes and accounts for approximately 90 % of all primary hepatic malignancies. HCC is the fifth most common cancer worldwide, with 600 000 new cases each year, and is the second leading cause of cancer-related deaths globally (Schütte et al., 2009; El-Serag, 2011 , 2012 . The highest rates of HCC are in areas of the world with high rates of chronic hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections, which are its major risk factors (Fung et al., 2009; Asim et al., 2010) . HCC incidence in the USA has tripled in the past 30 years, with approximately prevent eventual development of HCC in all individuals, with HCC incidence rates of over 3 % after 5 years and 8 % after 15 years (Akuta et al., 2008) . Additionally, amino acid substitutions in the HCV core region have been shown to be associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy (Seko et al., 2013) .
There is an urgent need to develop and validate more sensitive screening tests. At present, the major modalities for liver cancer surveillance among high-risk patients are serum alpha-fetoprotein (AFP) and ultrasonography, which suffer from unacceptably high rates of false negative test results (35-60 % in most studies) (Marrero et al., 2009) . Only a third of HCC is detected at a stage that allows potentially curative cancer therapies (Bruix & Sherman, 2005; Stravitz et al., 2008) . If detected at an early stage, liver transplantation, resection and locoregional therapies are associated with five-year survival rates of 50 % or greater (Bruix & Sherman, 2005; Stravitz et al., 2008) .
Accumulating evidence indicates that genetic subtypes (genotypes) of HCV differ in their potential to cause liver cancer. A recent review concluded that specific sequence variations in key regions of the HCV genome are associated with increased HCC risk and poorer survival, as well as interferon treatment failure, and show a high specificity of these associations (Asim et al., 2010) . Previous investigations have particularly implicated an association of increased risk of HCC with specific sequence variations in the HCV core gene in circulating virus (Akuta et al., 2007 (Akuta et al., , 2008 Fishman et al., 2009; Ogura et al., 2009; Hu et al., 2009; Fukuhara et al., 2010; Kobayashi et al., 2010; Nakamoto et al., 2010; Ahmad et al., 2011; Khaliq et al., 2011; El-Shamy et al., 2013; Seko et al., 2013) . However, all of these studies have been conducted in Asian populations and almost exclusively involve either HCV genotype (GT) 1b only or populations designated only as GT1. No studies have specifically evaluated HCV GT1a-infected subjects as a separate group, despite the fact that this genotype is highly prevalent in the USA and Europe. Two studies examined HCV GT4 in Egypt with differing results: one observed specific HCV core gene sequence variations correlated with increased HCC risk (Abdel-Hamid et al., 2007) and one did not (Zhang et al., 2011) . Notably, in all of these studies, the patient populations studied were heterogeneous in terms of disease severity, with a spectrum ranging from chronic hepatitis to cirrhosis. This potentially complicates specific associations with cancer development, as some of these sequence variations have been shown to be associated with different stages of disease progression rather than specifically with HCC (Horie et al., 1999; Eng et al., 2009; Ahmad et al., 2011; Khaliq et al., 2011) . A general trend for increased variability in HCV core gene sequence in HCC tissues and during progression to more advanced liver disease has also been noted previously (Horie et al., 1999; Khaliq et al., 2011) . Several investigations have demonstrated differences in HCV core gene sequences between tumour and nontumour tissue in the same liver (De Mitri et al., 1998; Horie et al., 1999; Delhem et al., 2001; Rüster et al., 2001; Alam et al., 2002; Ogata et al., 2002; Alestig et al., 2011) .
Among numerous sequence variations in the HCV genome that have been associated with HCC risk, those affecting codons 70 and 91 of the GT1b core region appear to increase the risk by six-to eightfold (Akuta et al., 2007 (Akuta et al., , 2008 Ogura et al., 2009; Fukuhara et al., 2010; Kobayashi et al., 2010; Nakamoto et al., 2010; Seko et al., 2013) , warranting further investigation. Of note, individuals with HCV core gene sequence variations in codons 70 and 91 who were cured of HCV infection were still found to be at significantly increased risk of developing HCC 5 to 15 years after cure of HCV infection compared with successfully treated individuals without these specific sequences (Akuta et al., 2008) . It is not clear, however, if specific sequence variations in the HCV core gene are associated with progression of liver disease or, alternatively, if these changes are the consequence rather than the cause of HCC development (Horie et al., 1999; Eng et al., 2009; Ahmad et al., 2011; Khaliq et al., 2011 ).
In the current study, we report the results of a pilot study to examine the association of HCC with specific sequence variations in the HCV GT1 core gene in a population of patients at the Georgetown University Medical Center with HCV-associated cirrhosis. This cohort study was limited to individuals with cirrhosis who were positive for serum HCV RNA. Thus, by design, we attempted to eliminate sequence variations that may be associated with chronic liver disease progression rather than with HCC. The first objective of the study was to determine if previously identified HCV core gene sequence variations, particularly those in codons 70 and 91, were associated with HCC in a non-Asian, HCV GT1-infected population (particularly GT1a-infected) typical of the USA. The second objective was to determine if additional sequence variations in the HCV core gene were associated with HCC risk in this population.
RESULTS
A panel of 25 specific nucleotide variations in 19 codons of the HCV core gene was detected exclusively in the HCV GT1a individuals with HCC (Table 1) . Each specific nucleotide change was present in a minority of individuals, and more than one-half of these individuals (18/23) harboured more than one HCV core sequence variation (Tables 2 and  3 ). A panel of 11 nucleotide differences in 9 codons of the GT1a HCV core gene occurred more frequently (Pv0.05) in the HCC-positive group and accounted for 21/23 (91 %) of GT1a HCC-positive individuals in this study (Panel A, Tables 1, 2 and 3). This panel included nucleotide changes in codon 91, but not codon 70. Sequence variations at only two codons in this panel were also observed in either one or two of the non-HCC subjects.
A second panel of 17 nucleotide changes in 13 codons of the GT1a HCV core gene was also identified (Panel B, HCV core gene mutations and HCC Table 1 ). All but one of these sequence variations were present exclusively in individuals with HCC, and since these were observed in fewer individuals overall, they were consequently not present in HCC + individuals at statistically different rates than the non-HCC subjects. Approximately one-half (12/25) of the nucleotide changes in both of these panels would produce amino acid changes in the HCV core protein (Tables 2 and 3 ).
There was no significant difference in the frequency of nucleotide changes at codon 70 in GT1a individuals with HCC (14/23 HCC + vs 13/26 HCC 2 ), consistent with previous associations of these nucleotide differences with advanced liver disease (Horie et al., 1999; Eng et al., 2009; Ahmad et al., 2011; Khaliq et al., 2011) . While nucleotide changes in codon 91 were found in a minority of GT1a subjects with HCC (4/23), this difference was statistically significant (P50.038) as these nucleotide sequences were not observed in any of the 26 GT1a subjects in the non-HCC group. As previously observed (Akuta et al., 2007 (Akuta et al., , 2008 Eng et al., 2009; Ogura et al., 2009; Fukuhara et al., 2010; Kobayashi et al., 2010; Nakamoto et al., 2010; Seko et al., 2013) , changes in codon 91 were always in a pair of nucleotides, creating a codon for methionine A panel of 11 sequence variations (in 9 codons) in the HCV GT1a core gene was collectively associated with 21/23 (91 %) of GT1a individuals diagnosed with HCC in this study. All but two of these sequence variants were never observed in the non-HCC group. An additional panel of 17 sequence variations (in 13 codons) potentially associated with HCC was observed. All sequence variations were present in more than one GT1a subject with HCC, and all but one were not observed in any of the subjects in the non-HCC group. Circulating virus in over half (18/23) of these individuals harboured more than one mutation (see Tables 2 and 3 
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Journal of General Virology 96 (Table 1) . Additionally, nucleotide changes in codon 70 were highly associated with changes in codon 91, being present in 3/4 of the HCV GT1a infected individuals (data not shown), as previously observed (Akuta et al., 2007 (Akuta et al., , 2008 Eng et al., 2009; Ogura et al., 2009; Fukuhara et al., 2010; Kobayashi et al., 2010; Nakamoto et al., 2010; Seko et al., 2013) .
Overall, no specific nucleotide variations in the HCV core gene present in 41 GT1b study subjects were found to be associated with HCC, including those in codons 91 and 70 (codon 70: 7/19 HCC + vs 9/22 HCC 2 ; codon 91: 7/19 HCC + vs 11/22 HCC 2 ) (data not shown). This finding is unexpected and needs to be examined in a larger population for confirmation. Previous studies reported that nucleotide changes in codon 91 were often present in populations of GT1b non-HCC subjects with a range of non-cirrhotic and cirrhotic liver disease at rates ranging from 22 to 29 % (Akuta et al., 2007 (Akuta et al., , 2008 Eng et al., 2009; Fishman et al., 2009; Hu et al., 2009; Ogura et al., 2009; Fukuhara et al., 2010; Kobayashi et al., 2010; Nakamoto et al., 2010; Seko et al., 2013) .
For the GT1a-infected study subjects, there were no significant correlations between HCC and the levels of HCV RNA, AFP, model for end-stage liver disease (MELD) score, age, sex, ethnicity or tumour stage (R 2 50.16 to 0.66, data not shown). There was no correlation between the number of HCV GT1a core gene nucleotide changes per person and levels of HCV RNA, AFP, MELD score, age, sex or ethnicity (R 2 50.10 to 0.31, data not shown).
In the GT1a subjects, nucleotide changes in the HCV core gene (including those not listed in Table 1 ) were very frequent overall and distributed throughout the core gene sequence (Fig. 1) . The mean ( + SD) number of total nucleotide changes in the HCV core gene observed per person was not, however, significantly different between the two clinical outcome groups (HCC + : 17 + 8, HCC 2 : 13 + 5). The total number of codons with nucleotide changes was high (119/190, 63 %) . Nine codons, including 70 and 91, displayed a frequency of variation greater than two standard deviations above mean levels: 68, 70, 90, 91, 99, 106, 126, 181, 190 (Fig. 1) . While the overall distribution of nucleotide changes in the HCV core gene was very similar between the two groups (data not shown), 31 codons contained mutations observed only in the HCC group, and 19 codons contained mutations observed only in the non-HCC group. However, essentially all of these individual sequence changes were observed in only one subject each.
DISCUSSION
In this pilot study we identified a panel (Panel A) of HCV core gene sequence variations in GT1a-infected individuals that were significantly (Pv0.05) associated with HCC. This panel collectively accounted for 91 % of HCV GT1a subjects with HCC in our study cohort. The remaining two GT1a subjects with HCC had sequence variations (at codons 282 and 486) that were assigned to a secondary panel that comprised changes that were more frequent in the HCC group but not statistically different from the non-HCC group (Panel B). Importantly, nearly all of these sequence variations were not observed in a group of matched subjects with cirrhosis but without HCC. These data report the first such observations specifically for HCV GT1a-infected subjects.
In this pilot study we sought to extend the previous findings of specific HCV GT1b core gene sequence variations in codons 70 and 91 associated with HCC to GT1a-infected individuals with cirrhosis. Our study demonstrated that, for HCV GT1a-infected individuals, sequence changes in codon 91, but not codon 70, were significantly associated with HCC. While sequence changes in codon 91 were relatively infrequent in these HCC + subjects, these changes were not observed in any of the subjects in the non-HCC group. We did not observe any correlation with HCC in the GT1b-infected subjects with cirrhosis in this study for either codon 91 or 70.
It was noted in our study that sequence variations in codon 91 that were previously associated with HCC in GT1b-infected individuals were much less frequent in GT1a-infected subjects. Only 4/49 (8 %) GT1a-infected subjects (all with HCC) carried the pair of mutations in codon 91 previously associated with HCC, while 18/41 (44 %) of GT1b-infected individuals harboured this pair of sequence changes in our study population [7/19 (37 %) HCC + vs 11/22 (50 %) HCC 2 ]. Previous studies reported these nucleotide changes in codon 91 in GT1b non-HCC subjects with a mixture of cirrhotic and noncirrhotic liver disease at frequencies of 22-29 % (Akuta et al., 2007 (Akuta et al., , 2008 Eng et al., 2009; Fishman et al., 2009; Hu et al., 2009; Ogura et al., 2009; Fukuhara et al., 2010; Kobayashi et al., 2010; Nakamoto et al., 2010; Seko et al., 2013) . Changes in codon 70 previously associated with HCC were present in a high proportion of either HCV GT1b (16/41) or GT1a (27/49) infected individuals in this study. It is unknown if the high prevalence of these specific sequence changes is related to the inclusion criterion that all subjects (HCC and non-HCC) in this study be cirrhotic.
For the GT1a-infected study subjects, there were no significant correlations between specific nucleotide changes and clinical parameters that correlated with hepatic dysfunction (such as MELD score) or tumour burden (AFP), demonstrating that the proposed biomarker panel appears highly specific to HCC and not the underlying chronic liver disease. There was little overlap of our panel of GT1a core gene sequence variations with nucleotide variations previously associated with HCC (Akuta et al., 2007 (Akuta et al., , 2008 Eng et al., 2009; Fishman et al., 2009; Hu et al., 2009; Ogura et al., 2009; Fukuhara et al., 2010; Kobayashi et al., 2010; Nakamoto et al., 2010; Ahmad et al., 2011; Khaliq et (Table 1 footnote), which may not be unexpected as previous studies were conducted almost exclusively in GT1b subjects, were conducted in populations of individuals with a wide range of liver disease, or reported for a mixed population of GT1a and 1b individuals.
would be the basis for research to examine potential mechanisms that would explain how these mutations are associated with HCV-induced tumour development.
HCV continues to be the predominant aetiology underlying HCC in the USA, accounting for 50-60 % of all cases (El-Serag & Kanwal, 2014) . Mathematical modelling has estimated that the number of HCV-associated HCC cases increased by 130 % between 2000 and 2009, with a projected 50 % increase between 2010 and 2019 (Davis et al., 2010) . The treatment of HCV has recently undergone a dramatic transformation with the advent of direct antiviral agents (DAA), which result in excellent rates of sustained virologic response (Kohli et al., 2014) . While the projected trajectory of HCV-related HCC incidence may change under the influence of these factors, even successful viral eradication does not completely negate the risk of developing HCC in those with underlying cirrhosis. Additionally, 45-70 % of affected individuals remain unaware of their infection status (Volk et al., 2009) . It is therefore likely that HCV-associated HCC will continue to represent a significant healthcare burden for which early detection methods are urgently needed.
Specific nucleotide changes in the HCV core gene identified in this study, especially Panel A, represent an initial test panel for assessing increased cancer risk in HCV GT1a-infected individuals with cirrhosis, including longitudinal studies. Most importantly, these sequence patterns need to be examined in larger populations of GT1a-infected individuals with cirrhosis and HCC to verify the utility of these nucleotide markers and possibly refine the panel into a smaller group that can be more readily tested.
METHODS
Study population. Consented subjects were individuals who were enrolled between 2008 and 2012 at the Georgetown University Transplant Institute with stored blood specimens at baseline and complete medical follow-up data. This protocol was approved by the Institutional Review Board of Georgetown University Medical Center. A total of 90 subjects who were positive for serum HCV RNA were included in the study (49 GT1a, 41 GT1b), 42 of whom had already developed HCC (23 GT1a, 19 GT1b) at the time of specimen retrieval from the biorepository in 2013. All patients were chronically HCVinfected, with cirrhosis (diagnosis based on clinical, imaging, biochemical or histological criteria), and positive for HCV RNA (no load cut-off). At the time of sample acquisition, none of the study subjects had received prior antiviral therapy. Study subjects were of mixed ethnicity (61 % Caucasian, 39 % African-American; none of Asian heritage).
Statistical analysis. We used chi-squared tests and t-tests to evaluate possible differences between groups of subjects, for categorical and continuous variables, respectively, using P50.05 as the criterion for statistical significance. Data analysis was performed using SAS, version 9. Neither gender, age, MELD score, nor HCV viral load varied significantly between the HCC and non-HCC cirrhosis groups or between carriers of HCV GT1a or GT1b infections (Table 4) . Other clinical and serological markers (e.g. AFP) also failed to discriminate the two outcome groups (data not shown).
Isolation and analysis of HCV core gene sequences. HCV RNA was isolated from 200ul frozen serum samples (TRIzol) and was reverse-transcribed using random hexamers (Promega) using standard procedures (16). Samples were then amplified using nested PCR (forward primers: 274F: AAGGCCTTGTGGTACTGCCTG, 318F: GGAGGTCTCGTAGAC CGTGCA (16); reverse primers: 995R: GTCSGCYGCCTCATACACAAT, 964R: GAGACARTCRTTC-GTGACATGGTA) to produce a fragment for analysis consisting of a complete HCV core gene sequence. Sequencing was performed by GeneWiz. Sequence quality was assessed at each nucleotide position using quality value: QV5210log 10 (Prob. of error); Prob. of error 1 % w QV520. Sequences with less than 500 nt, and/or QV larger than 20, were excluded. Sequences were aligned with CLUSTAL Omega (3\1). A contingency table was constructed for each nucleotide position to determine differences in nucleotide identity at each position and analysed for significance using Fisher's exact test. Reference sequences (from GenBank) used for analysis were: GT1a, EU255968, EU256032 and GT1b, FJ478453, EU155303.
Table 4. Study population demographics
Mean values are displayed with standard deviations. The demographics of the study population did not differ significantly between any of the subgroups.
All (N590)
HCC (2) 
